Tiffany Lee, PharmD, BCIDP

This highlighted study looks at using these 2 therapies concurrently for this infection.

Interests have recently skewed toward the use of carbapenem-sparing regimens in light of growing selection for carbapenem-resistant organisms.

Bezlotoxumab, a human monoclonal anti­body directed against Clostridioides diffi­cile toxin B, is currently indicated for the prevention of recurrent C diffi­cile infection